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Abstract
Background More and more studies demonstrated that genetic variation at C1GALT1
influences Gd-IgA1 level in IgAN. However, whether the expression of β1, 3- 
Assay for Gd-IgA1
Plasma Gd-IgA1 levels were detected using ELISA kit according to the manufacturer's specifications (IBL, Japan) [6] . Plasma samples were diluted in proportions of 1:50 with EIA buffer and incubation for 60min at R.T. with plate lid.
Then washing four times with wash buffer prepared labeled antibody were incubated for 30min. Plates were washed and added 50ul TMA solution incubation for 30min in dark. At last, the color reaction was stopped and the absorbance was measured at 450/625 nm with an EL312 Bio-Kinetics microplate reader (Bio-TekInstruments, Winooski, VT). 
B lymphocytes Isolation

RNA Extraction
Total cellular RNA was extracted from CD19 positive B lymphocytes using the TRIZOL Reagent (Invitrogen, USA). RNA quantity was determined using NanoDrop ND-1000 spectrophotometer. cDNA was synthesized using 300 ng total RNA with revert first-strand cDNA kit according to manufacturer's protocol (Promega, USA).
Quantitative Reverse Transcription PCR (RT-PCR)
cDNA was amplified with a 20 µL reaction mixture using SYBR Green PCR Master Mix (Roche, USA) in an Applied Biosystem 7500 Real-Time PCR System. GAPDH served as the endogenous control. The primer sequences were listed in Table 1 . The fold change between patients and controls was expressed by the 2 -△△CT method.
Ethics statement 7
The Medical Ethics Committee of Tianjin medical university general hospital approved the study protocol and informed written consent was obtained from all individuals. All study participants provided written informed consent for collection of blood samples, and for examination of clinical records relevant to the study.
Meta-analysis
Eligible studies were included if all criteria were met as follows: (1) Two reviewers independently extracted the data from each study, collected data separately and finally summarized. The following related variables of patients were collected: country, mean age, male, sample size and detection index) ( Table 2 ).
Risk of Bias
The Newcastle-Ottawa Scale (NOS) was used to assess the quality of included studies by judging them using three board perspectives: the selection of study groups, the comparability of study groups, and the measurement of exposure in study groups [7] .
Statistical analysis
The differences in gene expression levels between groups were compared using ANOVA and p value < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 17.0 software. In the review, for the continuous measurement of C1GALT1, C1GALT1C1 expression and β1, 3Gal-T activity, we used the weighted mean difference and square deviation (SD) between groups. We analyzed heterogeneity beyond chance using the I 2 statistic to describe the percentage of variability. We made graphic representations of potential publication bias using Begg's Funnel plots of the natural logarithm of the RR versus its standard error (SE) and assessed them visually. A 2-sided p value less than 0.05 was considered statistically significant, and all statistical analyses were performed using Review Manager 5.3 software.
Results
Baseline clinical characteristics of patients with IgAN
There were 16 males and 14 females with average age of 39.5 years. The median of proteinuria was 1.32 g/d and mean eGFR was 85.45 mL/min/1.73 m 2 of IgAN patients on biopsy. And the grading of the pathological lesions by Oxford classification is shown in Table 3 .
Patients with IgAN had low expression level of C1GALT1
The expression levels of C1GALT1 in B cells were detected in IgAN patients and healthy control. We found C1GALT1 expression levels were remarkably downregulated in IgAN patients (IgAN vs. controls: 1.01 ± 0.19 vs 1.43 ± 0.11, p = 9 0.04, Figure 1 ).
Expression of C1GALT1 related with the Gd-IgA1 levels
Using the GalNAc-specific monoclonal antibody KM55, we examined the plasma levels of Gd-IgA1 in patients with IgAN and healthy control. In our cohorts, the plasma level of Gd-IgA1 in patients with IgAN ranged from 8.55 to 14.48 U/mL, whereas it ranged from 3.97 to 12.15 U/mL in healthy control. We found that Gd-IgA1 levels were remarkable high in IgAN patients compared with healthy control (p < 0.001, Figure 2 ). And the mRNA levels of C1GALT1 were inversely correlated to Gd-IgA1 levels (r = -0.33, p < 0.001, Figure 3 ).
Meta-analysis
The literature search yielded 1052 articles, and eventually, six studies with 316 patients were included in our meta-analysis according to the inclusion criteria (Additional Figure 1 ). We included studies whose primary purpose was to elucidate the expression level and activity of C1GALT1 and the expression level of C1GALT1C1 in IgAN patients [5, [8] [9] [10] [11] [12] . Table 2 . These studies were performed from 1997 to 2016, with sample sizes ranging from 10 to 126.
Quality Assessment of Included Studies
The qualities of included studies, assessed with NOS (Newcastle-Ottawa Scale), are provided in Table 4 . The mean total score was 5 with a range from 4 to 6.
C1GALT1 mRNA expression
We added own results to the final meta-analysis to elucidate the mRNA expression data of C1GALT1. Six articles including 316 participants that analyzed the expression of β1, 3Gal-T were included. There was no significant difference between IgAN patients and the total control group (weighted mean difference, -0.48 [95% CI -1.29 to 0.32], p = 0.24; I2 = 93%, p for heterogeneity < 0.001) (Figure 4 ).
Subgroup analysis was performed according to different control group and different cell source. Four studies compared mRNA expression level of C1GALT1 in 106 IgAN patients and 44 disease controls and five studies conducted in 160 IgAN patients and 139 healthy controls. There was no apparent disparity between IgAN patients and non-IgAN patients (weighted mean difference, 0.26 [95% CI -0.08 to 0.60], p = 0.14; I2 = 0%, p for heterogeneity = 0.89) and healthy controls (weighted mean difference, -0.62 [95% CI -1.59 to 0.36], p = 0.21; I2 = 93%, p for heterogeneity < 0.001) ( Figure 5 ).
In circulation, B lymphocytes are the major cells for IgA1 production. To explore the causal factor of the lymphocytes abnormality in patients with IgAN, in terms of β1, 3 galactosyltransferase induced Gd-IgA1 production, we detected the mRNA expression of C1GALT1 in B lymphocytes. A total of 4 studies enrolled 81 patients and 88 controls. Finding for this outcome was that patients with IgAN had low levels of C1GALT1 gene expression in the B lymphocytes compared to control (weighted mean difference, 0.39 [95% CI 0.08 to 0.69], p = 0.01; I2 = 96%, p for heterogeneity < 0.001) ( Figure 6 ).
β1, 3Gal-T activity
Comparison of β1, 3Gal-T activity was reported in 2 trials including 46 persons, the result showed patients with IgAN had low levels of β1, 3Gal-T activity in the B cells compared to control (weighted mean difference, -2.43 [95% CI -4.33 to -0.52], p = 0.01; I 2 = 80%, p for heterogeneity = 0.03) (Figure 7 ).
C1GALT1C1 expression
We also explored the expression of C1GALT1C1 in different groups. There was no significant difference between IgAN patients and the total control group (weighted mean difference, -0.68 [95% CI -1.61 to 0.25], p = 0.15; I2 = 93%, p for heterogeneity < 0.001) (Supplement Figure 1 ). And the same result occurred between IgAN patients and non-IgAN patients (weighted mean difference, 0.20 [95% CI -0.99 to 0.59], p = 0.62; I2 = 80%, p for heterogeneity = 0.007) and healthy control (weighted mean difference, -0.80 [95% CI -1.90 to 0.29], p = 0.39; I2 = 81%, p for heterogeneity = 0.002, Supplement Figure 2 ). Even in the B lymphocytes the levels of C1GALT1C1 gene expression that between IgAN and the control group had no significant difference (weighted mean difference, -0.34 [95% CI -1.13 to 0.44], p = 0.39; I2 = 81%, p for heterogeneity = 0.002, Supplement Figure 3 ). In the meantime, subgroup meta-analysis was conducted between Chinese and UK subjects. The result showed there were no different from the levels between different ethnic population (weighted mean difference, -0.66 [95% CI -2.09 to 0.77] vs -0.65 [95% CI -1.55 to 0.25], p for heterogeneity = 0.99, Supplement Figure 4 ).
Risk of bias
Formal statistical test showed that there was no publication bias in the expression of C1GALT1 compared between IgAN patients and total control (Begg's test p = 0.452), which was showed in Additional Figure 2 .
discussion
In recent years, the role of galactose-deficiency of IgA1 in IgAN is widely recognized, thus how to cause the occurrence of galactose-deficiency has become the focus of the research [13] . It demonstrates that common variation at C1GALT1
influences Gd-IgA1 level in IgAN [3, 14] . In this study we found expression levels of lymphocytes, which inducing increased production of aberrantly glycosylated IgA1 molecules, ultimately contributed to IgAN pathogenesis [17] . Thus, according to these studies and views, it seems to closely show that this downregulation might be one of the fundamental pathogenic abnormalities in IgAN.
In the meta-analysis, patients with IgAN had low β1, 3Gal-T activity in the B lymphocytes compared to control group. However, it is not clarified whether abnormalities of IgA1 O-glycosylation was a result from reduced β1, 3Gal-T activity,
there is a paucity of information on the regulation of activity of this glycosyltransferase. Cosmc, encoded by C1GALT1C1, is core 1 beta-3galactosyltransferase specific chaperone, and important for IgA1 glycosylation [18] .
The expression of C1GALT1C1 was closely related to the activity of β1, 3Gal-T, and it was previously reported to be down-regulated and associated with IgA1 glycosylation [19] . Therefore we analyzed the expression of C1GALT1C1 by metaanalysis, the result showed that there was no significant difference between IgAN patients and the total control group. Furthermore, the results were not modified by different ethnic population, different control group and different cell source. Further studies were needed for a better understanding of the potential mechanism of the change of β1, 3Gal-T activity.
limitations
Our study does, however, have several limitations. Firstly, because of the lack of sufficient data, a subgroup analysis explored the heterogeneity between C1GALT1 and the pathogenesis of IgAN is not conducted. Secondly, the specific quantification methods of qPCR experiments and internal control differed between studies, which may affect the effect sizes. Thirdly, the sample size of our study is small and the 14 involved studies have poor quality assessment. We will further expand the sample size to verify the expression of C1GALT1 in IgA patients and its relationship with Gd-IgA1 levels.
Conclusion
We found expression level of C1GALT1 was remarkably downregulated in IgAN Table 1 . Primers Used to amplify the C1GALT1 and GAPDH Genes Table 2 . Characteristics of the studies included in meta-analysis 
